年轻乳腺癌幸存者的第二原发乳腺癌
该前瞻性研究纳入1297例40岁及以下、诊断为0至III期乳腺癌并接受单侧乳房切除或肿块切除术的女性,分析第二原发乳腺癌的累积发生率和危险因素。中位随访10.0年,685例可分析患者中17例(2.5%)发生第二原发乳腺癌,10年风险在无致病性变异者为2.2%、携带者为8.9%。携带致病性变异和原发原位癌与第二原发乳腺癌风险升高相关。
要点
- 年轻乳腺癌幸存者10年第二原发乳腺癌累积发生率为2.5%。
- 无致病性变异者10年风险2.2%,携带者8.9%。
- 致病性变异携带者风险升高(sHR 5.27),原发原位癌者风险升高(sHR 5.61)。
核心结论
- 年轻乳腺癌幸存者中无致病性变异者在诊断后10年内发生第二原发乳腺癌的风险较低。
- 种系基因检测结果可能为该人群的治疗决策和随访护理提供信息。
研究设计与样本
- 前瞻性队列研究(Young Women's Breast Cancer Study),纳入1297例40岁及以下、2006年8月至2015年6月诊断为0至III期乳腺癌的女性。
- 分析纳入685例接受单侧乳房切除或肿块切除术作为初始手术的患者,平均(SD)原发乳腺癌诊断年龄36(4)岁。
- 通过患者调查和病历回顾收集人口学、基因检测、治疗和结局数据,采用时间事件分析考虑竞争风险,Fine-Gray子分布风险模型评估临床因素与第二原发乳腺癌风险的关联。
- 数据分析时间为2023年1月至5月。
主要发现
- 中位(IQR)随访10.0(7.4-12.1)年,17例患者(2.5%)发生第二原发乳腺癌,其中2例为肿块切除后同侧乳房癌症。
- 从原发乳腺癌诊断到第二原发乳腺癌的中位(IQR)时间为4.2(3.3-5.6)年。
- 在577例接受基因检测的女性中,10年第二原发乳腺癌风险在无致病性变异者为2.2%(544例中12例),在致病性变异携带者为8.9%(33例中3例)。
- 多变量分析中,致病性变异携带者相比非携带者第二原发乳腺癌风险更高(sHR 5.27;95% CI 1.43-19.43)。
- 原发原位癌相比浸润性癌的女性第二原发乳腺癌风险更高(sHR 5.61;95% CI 1.52-20.70)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为种系基因检测结果可能为该人群的治疗决策和随访护理提供信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Among women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that their risk of a second primary BC (SPBC) is higher than that of women who are older when they develop a first primary BC. OBJECTIVE: To estimate cumulative incidence and characterize risk factors of SPBC among young patients with BC. DESIGN, SETTING, AND PARTICIPANTS: Participants were enrolled in the Young Women's Breast Cancer Study, a prospective study of 1297 women aged 40 years or younger who were diagnosed with stage 0 to III BC from August 2006 to June 2015. Demographic, genetic testing, treatment, and outcome data were collected by patient surveys and medical record review. A time-to-event analysis was used to account for competing risks when determining cumulative incidence of SPBC, and Fine-Gray subdistribution hazard models were used to evaluate associations between clinical factors and SPBC risk. Data were analyzed from January to May 2023. MAIN OUTCOMES AND MEASURES: The 5- and 10- year cumulative incidence of SPBC. RESULTS: In all, 685 women with stage 0 to III BC (mean [SD] age at primary BC diagnosis, 36 [4] years) who underwent unilateral mastectomy or lumpectomy as the primary surgery for BC were included in the analysis. Over a median (IQR) follow-up of 10.0 (7.4-12.1) years, 17 patients (2.5%) developed an SPBC; 2 of these patients had cancer in the ipsilateral breast after lumpectomy. The median (IQR) time from primary BC diagnosis to SPBC was 4.2 (3.3-5.6) years. Among 577 women who underwent genetic testing, the 10-year risk of SPBC was 2.2% for women who did not carry a pathogenic variant (12 of 544) and 8.9% for carriers of a pathogenic variant (3 of 33). In multivariate analyses, the risk of SPBC was higher among PV carriers vs noncarriers (subdistribution hazard ratio [sHR], 5.27; 95% CI, 1.43-19.43) and women with primary in situ BC vs invasive BC (sHR, 5.61; 95% CI, 1.52-20.70). CONCLUSIONS: Findings of this cohort study suggest that young BC survivors without a germline pathogenic variant have a low risk of developing a SPBC in the first 10 years after diagnosis. Findings from germline genetic testing may inform treatment decision-making and follow-up care considerations in this population.
引用
- Brantley KD, Rosenberg SM, Collins LC, et al. Second Primary Breast Cancer in Young Breast Cancer Survivors. JAMA Oncol. 2024. PMID: 38602683. doi:10.1001/jamaoncol.2024.0286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。